Latest / Stock Movers / Apple Slides, Amazon Surges, Replimune Soars as FDA Panel Supports Drug
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, podcasts, radio news.
- 0:08Speaker 2: The Stock Movers report your roundup of companies making moves
- 0:12Speaker 2: in the stock market. Harnessing the power of Bloomberg data.
- 0:16Speaker 3: See what some of the stocks are on the move today.
- 0:18Speaker 3: We can do that with Avalon Purnell Color coordinated Avalon
- 0:22Speaker 3: Purnell Equities reporter for Bloomberg News. Avlon What do you
- 0:25Speaker 3: got for?
- 0:25Speaker 1: We have to start off with Apple, that's ticker AAPL,
- 0:28Speaker 1: currently dropping about nine point two percent most inter day
- 0:31Speaker 1: since last April. And while Apple did report third quarter
- 0:35Speaker 1: results that largely surpassed expectations, bears are largely focused on
- 0:39Speaker 1: the missus, mainly Apple services and also China based revenue,
- 0:43Speaker 1: which fell short of expectations. It also forecasts revenue growth
- 0:46Speaker 1: that was a little bit weaker than expected. Part of
- 0:49Speaker 1: this is all coming from softer mobile gaming trends and
- 0:52Speaker 1: also meaningful pressure from the memory crunch. If you remember
- 0:55Speaker 1: just last month, supply chain shortages and also really fast
- 0:59Speaker 1: rising memory costs forced Apple to raise prices on MacBooks
- 1:03Speaker 1: and iPads. Vital Knowledge writing earlier that the results are
- 1:07Speaker 1: underwhelming given the weakness and no segments, especially since services
- 1:10Speaker 1: account for so much of Apple's premium pe.
- 1:13Speaker 2: You know.
- 1:14Speaker 1: But Apple has a way of turning those shortages into
- 1:16Speaker 1: a good thing, because people lining up to buy the
- 1:18Speaker 1: stuff is always like signaling to everyone else.
- 1:20Speaker 3: Must have, must have. And if you're a hedge fund
- 1:22Speaker 3: manager and this is your core position, you're buying stock today,
- 1:25Speaker 3: and that's on a separate.
- 1:26Speaker 2: P and L.
- 1:27Speaker 3: That's like where I worked. Portfolio manager had the pl
- 1:30Speaker 3: for the main position, the trader had a separate P
- 1:32Speaker 3: and L to trade around it. I got a little cheap,
- 1:34Speaker 3: I buy a little bit more, got a little bit
- 1:36Speaker 3: above where you guys thought it should be near turn
- 1:37Speaker 3: you sell it and you make you take a big
- 1:39Speaker 3: cut of that.
- 1:40Speaker 1: So you keep adjusting that position, all right. Next up
- 1:42Speaker 1: Evlon Amazon another Max seven that's ticker AMZN, currently soaring
- 1:47Speaker 1: about fourteen percent most interday since twenty twenty two, and
- 1:50Speaker 1: that's after the company reported its fifth straight quarter of
- 1:53Speaker 1: cloud computing revenue acceleration. The second quarter results are definitely
- 1:58Speaker 1: easing some investors' concerns about how much Amazon is spending
- 2:01Speaker 1: to meet that increasing demand for AI. Morgan Stanley writing
- 2:05Speaker 1: that AWS delivered accelerating growth, surging profitability, and a better
- 2:09Speaker 1: backlog to give the market even more confidence moving forward
- 2:12Speaker 1: in the return on investment cost ahead height one more
- 2:15Speaker 1: last one is Replemoon. That's ticker ripl have to bring
- 2:18Speaker 1: in a biotech. It is currently surging ninety one percent,
- 2:21Speaker 1: most injur day since October, and that's after an advisory
- 2:24Speaker 1: panel at the FDA voted to support the drug last night.
- 2:28Speaker 1: The positive outcome already spurring upgrades at Canter and also
- 2:31Speaker 1: Piper Sandler, which note that the positive vote materially increases
- 2:35Speaker 1: the likelihood that the FDA may actually reverse its previous
- 2:38Speaker 1: rejection of their skin cancer drug. It really has been
- 2:41Speaker 1: a rollercoaster ride for the stock this week, though earlier
- 2:44Speaker 1: it sank more than thirty percent after the FDA released
- 2:47Speaker 1: briefing documents that showed an uphill battle for the drug,
- 2:50Speaker 1: and now after this the FDA's decision, which could come
- 2:53Speaker 1: as soon as later today, some analysts a could actually
- 2:55Speaker 1: end up being positive.
- 2:57Speaker 2: The stock mover's report from blue Burg Radio. Check back
- 3:01Speaker 2: with us throughout the day for the latest roundup of
- 3:04Speaker 2: companies making news on Wall Street and for the latest
- 3:07Speaker 2: market moving headlines. Listen to Bloomberg Radio Live. Catch us
- 3:11Speaker 2: on YouTube Bloomberg Dot com and on Applecarplay and Android
- 3:15Speaker 2: Auto with the Bloomberg Business App.